Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418102 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL29401087 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL29400989 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL15806915 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| Hydrochloric Acid SCHEMBL23455559 | 0.99 | MDM4 (0.59) | MDM4TP53KMT2ACASP3MDM2 | |
| Hydrochloric Acid SCHEMBL16620346 | 0.99 | MDM4 (0.59) | MDM4TP53KMT2ACASP3MDM2 | |
| Hydrochloric Acid SCHEMBL31370422 | 0.99 | MDM4 (0.59) | MDM4TP53KMT2ACASP3MDM2 | |
| Trifluoroacetic Acid SCHEMBL4363454 | 0.94 | MDM4 (0.55) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL29541007 | 0.90 | MDM4 (0.58) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL16095190 | 0.90 | MDM4 (0.58) | MDM4TP53KMT2ACASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12016836-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230263760-A1 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | LAPIX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11648225-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20050080119-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2005-04-14 | — | — | US | disclosed |
| US-20050008573-A1 | Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri) | BRACCO IMAGING S.P.A. (IT) | 2005-01-13 | — | — | US | disclosed |
| US-6803384-B2 | FOR THERAPY OF REPERFUSION INJURY | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| EP-1412383-A2 | PEPTIDES CONJUGATES, THEIR DERIVATIVES WITH METAL COMPLEXES AND USE THEREOF FOR MAGNETIC RESONANCE IMAGING (MRI) | Bracco Imaging S.p.A. (IT) | 2004-04-28 | — | — | EP | disclosed |
| US-20040006236-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003014157-A2 | PEPTIDES CONJUGATES, THEIR DERIVATIVES WITH METAL COMPLEXES AND USE THEREOF FOR MAGNETIC RESONANCE IMAGING (MRI) | BRACCO IMAGING S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| US-20020052512-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2002-05-02 | — | — | US | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1121342-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021920-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | MDM4 672/4885TP53 75/4885KMT2A 3513/4885 |
| US-20230263760-A1 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | HLA-DRB1, SLC11A2, CD74 | MDM4 4357/4885TP53 1195/4885KMT2A 1863/4885 |
| US-11648225-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | HLA-DRB1, SLC11A2, CD74 | MDM4 4357/4885TP53 1195/4885KMT2A 1863/4885 |
| US-20040006236-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | MDM4 4838/4885TP53 3585/4885KMT2A 3790/4885 |
| US-12016836-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | HLA-DRB1, SLC11A2, CD74 | MDM4 4357/4885TP53 1195/4885KMT2A 1863/4885 |
| US-20020052512-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | MDM4 4838/4885TP53 3585/4885KMT2A 3790/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885KMT2A 2293/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM4 1648/4885TP53 614/4885KMT2A 3083/4885 |
| US-20050080119-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | MDM4 4842/4885TP53 3807/4885KMT2A 4000/4885 |
| US-20050008573-A1 | Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri) | CCKAR, SSTR3, SSTR1 | MDM4 2472/4885TP53 1891/4885KMT2A 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.